Compare Cytokinetics Inc (CYTK) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.51 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 8.6× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| CYTK | VTIP | |
|---|---|---|
Market Cap | $8.50B | $73.20B |
Volume | 2,395,556 | 2,480,668 |
Sector | Health | — |
52-Week High | $87.26 | $50.46 |
52-Week Low | $54.76 | $48.38 |
Typical Hold Time | 19 Days | 91 Days |
Enterprise Value | $8.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
VTIP trades at $48.46, up 0.08% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The ETF, focused on short-term inflation-protected securities, shows strong institutional interest, with firms like NewEdge Advisors increasing positions by 45.5% in Q2 2026 (SEC filing, September 2026). Recent news highlights its role in hedging inflation amid rising energy prices and Fed rate hikes.
The outlook for VTIP is supported by its inflation-hedging appeal in a high-rate environment, but risks include interest rate sensitivity and competition from other TIPS ETFs. Wall Street sentiment is cautious yet constructive, given its low-cost structure and short-duration focus, positioning it as a defensive allocation for investors seeking inflation protection without significant rate risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
